News

The latest approval for Fragmin is for the blood thinner to be used for reducing symptomatic venous thromboembolism (VTE) in pediatric patients, aged one month and older. The

B7451012 was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12

Takeda has granted a license to Phathom for the development and exclusive commercialization rights to vonoprazan in the United States, Europe and Canada in exchange for upfront cash

According to the company, tolimidone significantly reduced HbA1c in comparison to placebo in the mid-stage trial as per the analysis of all patients who were subjected to the

Venclexta/Venclyxto is a first-in-class targeted medicine that will selectively bind and restrict the B-cell lymphoma-2 (BCL-2) protein, while Gazyva/Gazyvaro is an engineered monoclonal antibody that will attach to

The results were presented by Eric D. Donnenfeld, M.D., last week at the 2019 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS•ASOA)

ElevateBio is backed by $150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in

This is the first collaboration leveraging the ZymeLink platform and represents Zymeworks’ third technology platform licensed to a collaborator. “We believe this first ZymeLink licensing deal provides further

The approval was based on data from the phase III Javelin Renal 101 study, in which the combination significantly improved median progression-free survival (PFS) compared against sunitinib by